Global Biologics Contract Manufacturing Market to grow at a CAGR of 9.39% by 2032, Evaluates DelveInsight | AGC Biologics, Boehringer Ingelheim, Catalent, Cell Therapies, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, KBI Biopharma, Kemwel

According to DelveInsight's analysis, The increasing incidence of chronic conditions such as cancer, diabetes, and autoimmune diseases is driving demand for biologics, prompting pharmaceutical companies to outsource large-scale production to contract manufacturers. At the same time, a strong pipeline of biologics-including monoclonal antibodies, vaccines, and biosimilars-requires adaptable manufacturing solutions to efficiently meet expanding market demand. Advances in biotechnology, such as recombinant DNA technology and improved expression systems, are streamlining development processes, making contract manufacturing an attractive option for scalable production.

Additionally, the surge in product development activities by both emerging biotech companies and major pharmaceutical firms is fostering greater collaboration with CMOs and CDMOs to speed up market entry and reduce costs. Collectively, these trends are fueling the growth of the biologics contract manufacturing market, addressing the industry's need for high-quality, scalable, and flexible manufacturing solutions throughout the forecast period from 2025 to 2032.

DelveInsight's "Biologics Contract Manufacturing Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Biologics Contract Manufacturing companies actively working in the market.

To know more about why North America is leading the market growth in the Biologics Contract Manufacturing market, get a snapshot of the report Biologics Contract Manufacturing Market Trends
https://www.delveinsight.com/sample-request/biologics-contract-manufacturing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Biologics Contract Manufacturing Overview
Biologics contract manufacturing refers to outsourcing the production of biologic drugs-such as monoclonal antibodies, vaccines, cell and gene therapies, and recombinant proteins-to specialized third-party companies known as Contract Manufacturing Organizations (CMOs) or Contract Development and Manufacturing Organizations (CDMOs). These manufacturers provide services including process development, scale-up, formulation, analytical testing, and large-scale production under strict regulatory standards (e.g., GMP). Biologics contract manufacturing helps pharmaceutical and biotech companies reduce infrastructure costs, speed up time to market, and access specialized expertise and technologies needed for the complex manufacturing of biologic therapies.

DelveInsight Analysis: The global biologics contract manufacturing market size was valued at USD 23,240.99 million in 2024 and is anticipated to grow at a CAGR of 9.39% from 2025 to 2032, reaching approximately USD 47,494.63 million by 2032.

Biologics Contract Manufacturing Market Insights
Geographically, North America is anticipated to lead the biologic contract manufacturing organization market in 2024, driven by multiple factors. The region's dominance is fueled by the growing burden of chronic diseases like cancer, autoimmune disorders, and cardiovascular conditions, which is increasing the demand for biologics. North America also hosts numerous major biopharmaceutical companies and contract manufacturing organizations (CMOs) equipped with advanced manufacturing technologies, including expertise in cell culture, fermentation, and downstream processing. Additionally, rising R&D investments, supportive regulatory policies, and government efforts to promote biotech innovation are further boosting market expansion. The presence of key industry players, a strong biologics development pipeline, and increasing outsourcing by pharmaceutical companies further solidify North America's leading position in this sector.

To read more about the latest highlights related to Biologics Contract Manufacturing, get a snapshot of the key highlights entailed in the Biologics Contract Manufacturing
https://www.delveinsight.com/report-store/biologics-contract-manufacturing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Recent Developments in the Biologics Contract Manufacturing Market Report
• In October 2024, Enzene Biosciences unveiled EnzeneXTM 2.0, the latest advancement of its Fully-Connected Continuous ManufacturingTM (FCCMTM) technology for biologics, at CPHI Milan 2024.
• In August 2024, NEC Bio Therapeutics and AGC Biologics announced a partnership to produce personalized cancer vaccines.
• Thus, owing to such developments in the market, rapid growth will be observed in the Biologics Contract Manufacturing market during the forecast period

Key Players in the Biologics Contract Manufacturing Market
Some of the key market players operating in the Biologics Contract Manufacturing market include- AGC Biologics, Boehringer Ingelheim, Catalent, Cell Therapies, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, KBI Biopharma, Kemwell Biopharma, Lonza, Miltenyi Biotec, Minaris Regenerative Medicine, Samsung Biologics, Sandoz, Vetter Pharma, WuXi Biologics, Sanofi, Kymab, Novartis Pharma AG, Lindy Biosciences, Siegfried AG, and others.

Which MedTech key players in the Biologics Contract Manufacturing market are set to emerge as the trendsetter explore @ Key Biologics Contract Manufacturing Companies
https://www.delveinsight.com/sample-request/biologics-contract-manufacturing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Analysis on the Biologics Contract Manufacturing Market Landscape
As more companies prioritize personalized medicine approaches, including antibody-drug conjugates (ADCs) and immune checkpoint inhibitors, the demand for biologics contract manufacturing is steadily increasing. Monoclonal antibodies, in particular, are significantly influencing the expansion of the biologics manufacturing market. For example, in December 2024, Eurofins CDMO Alphora Inc. announced plans to build a 112,000 sq ft GMP biologics manufacturing facility in Mississauga, Ontario. This facility will focus on producing monoclonal antibodies and protein therapies for both clinical trials and commercial use, with completion targeted for 2026.
Collectively, these factors are expected to strengthen this market segment, driving the overall growth of the global biologics contract manufacturing industry.

Scope of the Biologics Contract Manufacturing Market Report
• Coverage: Global
• Study Period: 2022-2032
• Biologics Contract Manufacturing Market Segmentation By Manufactured Type: Cell-Based Biologics, Gene-Based Biologics, Monoclonal Antibodies, Vaccines, Recombinant Protiens, and Others
• Biologics Contract Manufacturing Market Segmentation By Type of Expression System : Microbial, Mammalian, and Others
• Biologics Contract Manufacturing Market Segmentation By Application Type: Oncology, Immunology, Cardiology, Neurological, and Others
• Biologics Contract Manufacturing Market Segmentation By End-User: Hospitals and Specialty Clinics
• Biologics Contract Manufacturing Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
• Key Biologics Contract Manufacturing Companies: AGC Biologics, Boehringer Ingelheim, Catalent, Cell Therapies, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, KBI Biopharma, Kemwell Biopharma, Lonza, Miltenyi Biotec, Minaris Regenerative Medicine, Samsung Biologics, Sandoz, Vetter Pharma, WuXi Biologics, Sanofi, Kymab, Novartis Pharma AG, Lindy Biosciences, Siegfried AG, and others
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Interested in knowing how the Biologics Contract Manufacturing market will grow by 2032? Click to get a snapshot of the Biologics Contract Manufacturing Market Analysis
https://www.delveinsight.com/sample-request/biologics-contract-manufacturing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Biologics Contract Manufacturing Market Report Introduction
2 Biologics Contract Manufacturing Market Executive summary
3 Regulatory and Patent Analysis
4 Biologics Contract Manufacturing Market Key Factors Analysis
5 Porter's Five Forces Analysis
6 COVID-19 Impact Analysis on Biologics Contract Manufacturing Market
7 Biologics Contract Manufacturing Market Layout
8 Global Company Share Analysis - Key Biologics Contract Manufacturing Companies
9 Company and Product Profiles
10 Project Approach
11 Biologics Contract Manufacturing Market Drivers
12 Biologics Contract Manufacturing Market Barriers
13 About DelveInsight

Latest Reports by DelveInsight
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Dry Eye Disease Market: https://www.delveinsight.com/report-store/dry-eye-disease-market-insights
• Nonalcoholic Steatohepatitis Market: https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market
• Female Infertility Market: https://www.delveinsight.com/report-store/female-infertility-market
• Gonorrhea Market: https://www.delveinsight.com/report-store/gonorrhea-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Structural Heart Devices Market: https://www.delveinsight.com/report-store/structural-heart-devices-market-market

Contact Us
Gaurav Bora
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.